Get the Stockscreener App
19.71
2.18%
-0.44
After Hours:
19.65
-0.06
-0.30%
Beam Therapeutics Inc stock is traded at $19.71, with a volume of 2.39M.
It is down -2.18% in the last 24 hours and up +15.87% over the past month.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
See More
Previous Close:
$20.15
Open:
$19.93
24h Volume:
2.39M
Relative Volume:
1.15
Market Cap:
$1.98B
Revenue:
$352.57M
Net Income/Loss:
$-143.01M
P/E Ratio:
-10.89
EPS:
-1.81
Net Cash Flow:
$-153.40M
1W Performance:
-5.92%
1M Performance:
+15.87%
6M Performance:
-23.96%
1Y Performance:
-37.71%
1-Day Range:
$19.48
$20.14
1-Week Range:
$19.48
$22.05
52-Week Range:
$13.53
$35.25
Beam Therapeutics Inc Stock (BEAM) Company Profile
Name
Beam Therapeutics Inc
Sector
Industry
Phone
857-327-8775
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
19.71 | 2.03B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-10-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Jan-29-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-23-24 | Initiated | H.C. Wainwright | Buy |
| Jan-29-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-08-23 | Downgrade | Jefferies | Buy → Hold |
| Oct-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-20-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-13-22 | Initiated | Citigroup | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Jan-05-22 | Initiated | Guggenheim | Buy |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Sep-24-21 | Resumed | Stifel | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Redburn | Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-16-21 | Initiated | Wells Fargo | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Aug-05-20 | Initiated | William Blair | Outperform |
| Mar-02-20 | Initiated | Barclays | Overweight |
| Mar-02-20 | Initiated | JP Morgan | Overweight |
| Mar-02-20 | Initiated | Jefferies | Buy |
| Mar-02-20 | Initiated | Wedbush | Outperform |
View All
Beam Therapeutics Inc Stock (BEAM) Latest News
What is Beam Therapeutics Inc. company’s growth strategyMarket Forecast Opportunities For Every Investor - jammulinksnews.com
Is it the right time to buy Beam Therapeutics Inc. stockEntry Signal Growth Plan For Every Investor - jammulinksnews.com
What makes Beam Therapeutics Inc. stock price move sharplyChart Pattern Trend Scanner With Low Risk - jammulinksnews.com
How volatile is Beam Therapeutics Inc. stock compared to the marketValue Investing Picks For Consistent Profits - jammulinksnews.com
Beam Therapeutics Inc. stock trendline breakdownReal Time Alerts Based on AI Prediction Triggered - metal.it
Why Beam Therapeutics Inc. stock attracts strong analyst attentionReal-Time Trade Insights Spark Market Reactions - metal.it
Will Beam Therapeutics Inc. Hold Gains Into ClosePotential Breakout Stock List Published This Week - metal.it
Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know - Yahoo Finance
Beam Therapeutics Inc. Hits Oversold Level on RSI IndicatorReliable Investment Entry Signals Confirmed by Charts - metal.it
Published on: 2025-07-29 04:04:17 - metal.it
Competitive Positioning of Beam Therapeutics Inc.: Is It Leading or LaggingAlpha Focused Technical Trade Signals Gain Attention - metal.it
How many analysts rate Beam Therapeutics Inc. as a “Buy”Get expert advice on portfolio optimization - jammulinksnews.com
What is the risk reward ratio of investing in Beam Therapeutics Inc. stockFree Trend-Following Techniques - jammulinksnews.com
What is the dividend policy of Beam Therapeutics Inc. stockFree Market Volatility Navigation Tips - jammulinksnews.com
Is Beam Therapeutics Inc. stock overvalued or undervaluedAchieve rapid wealth accumulation with smart picks - jammulinksnews.com
When is Beam Therapeutics Inc. stock expected to show significant growthBuild a winning investment strategy - jammulinksnews.com
Why is Beam Therapeutics Inc. stock attracting strong analyst attentionFree Consultation - jammulinksnews.com
Published on: 2025-07-27 19:29:01 - jammulinksnews.com
Is Beam Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis InsideFree Real-Time Trading Opportunities - beatles.ru
What drives Beam Therapeutics Inc. stock priceSky-high profits - PrintWeekIndia
Will Beam Therapeutics Inc. stock benefit from interest rate changesFree Market Dynamics Reports - jammulinksnews.com
What makes Beam Therapeutics Inc. stock attractive to long term investorsSuperior stock selection - jammulinksnews.com
What institutions are buying Beam Therapeutics Inc. stock nowOutperformance with explosive growth - jammulinksnews.com
What analysts say about Beam Therapeutics Inc. stockFree Popular Stock Recommendations - PrintWeekIndia
Trading (BEAM) With Integrated Risk Controls - news.stocktradersdaily.com
Can Beam Therapeutics Inc. stock recover from recent declineFree Smart Trading Workshop - jammulinksnews.com
Beam Therapeutics Inc. Stock Analysis and ForecastFree Stock Movement Tracking - Autocar Professional
Is Beam Therapeutics Inc. a good long term investmentRobust financial gains - jammulinksnews.com
Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail
Beam Therapeutics (BEAM) Announces Acquisition of an Early-Stage Life Sciences Company - MSN
Beam Therapeutics Inc Stock (BEAM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):